- The USPTO has awarded Patent No. 10,000,772 to CRISPR Therapeutics (CRSP -0.7%), Intellia Therapeutics (NTLA -2.5%) and Caribou Biosciences covering methods of using optimized guide RNA formats in certain environments, including eukaryotic cells (human, animal, plant), which modify the part of a guide RNA that interacts with the CRISPR/Cas9 enzyme.
- The application, filed in May 2012, broadly covers the CRISPR-Cas9 gene editing technology invented by Jennifer Doudna and Emmanuelle Charpentier's research teams.
- The new patent award is not related to the USPTO's decision to terminate an interference between another Cal-Berkeley patent application and one owned by the Broad Institute, Harvard University and MIT. An appeal of the decision was heard on April 30 by the U.S. Court of Appeals for the Federal Circuit. A decision is pending.
- Related ticker: (EDIT -1.3%)
- Now read: Rounds Report: Crispr Rallied While The FDA Approved Lumivascular
Original article